Paper Details

  1. Home
  2. Paper Details

[Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: 
A Case Report and Literature Review].

Author: YangHaixiang, ZhuWei

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Alectinib, an ALK-tyrosine kinase inhibitor, has shown promising clinical outcomes in patients with ALK-positive non-small cell lung cancer (NSCLC). Early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This report retrospectively analyzes the diagnosis and treatment of an ALK-positive NSCLC patient admitted to Baotou Central Hospital in April 2020, emphasizing the importance of early intervention for adverse drug reactions.
Paper Details　
Original Abstract of the Article :
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has gr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503986/

データ提供：米国国立医学図書館（NLM）

Treating ALK Positive Non-small Cell Lung Cancer: Alectinib and a Case Report

This study delves into the treatment of ALK positive non-small cell lung cancer, a specific type of lung cancer with a unique genetic mutation. The authors present a case report of a patient diagnosed with this type of cancer, highlighting the use of alectinib, an ALK-tyrosine kinase inhibitor, as a treatment option. They also provide a comprehensive literature review, summarizing the current understanding of alectinib's effectiveness in treating ALK positive non-small cell lung cancer.

A New Frontier in Lung Cancer Treatment: Alectinib and ALK Positive Non-small Cell Lung Cancer

This study sheds light on the growing field of targeted therapies for specific types of lung cancer. The authors' case report and literature review provide valuable insights into the effectiveness of alectinib in treating ALK positive non-small cell lung cancer, emphasizing the importance of personalized treatment approaches based on genetic mutations.

Hope for Lung Cancer Patients: Alectinib and its Potential

This study offers a beacon of hope for patients diagnosed with ALK positive non-small cell lung cancer. The authors' research highlights the potential of alectinib as a targeted therapy, providing a more effective and potentially less toxic treatment option compared to traditional chemotherapy. This research emphasizes the importance of ongoing research and development in personalized medicine, offering new hope for patients with specific genetic mutations.

Dr.Camel's Conclusion

This study highlights the progress being made in the treatment of lung cancer, specifically focusing on the use of alectinib for ALK positive non-small cell lung cancer. The authors' research emphasizes the importance of personalized medicine, where treatment strategies are tailored to the individual patient's genetic profile. This approach holds immense promise for improving treatment outcomes and enhancing quality of life for patients with this devastating disease.
Date :
  1. Date Completed 2022-01-21
  2. Date Revised 2022-01-21
Further Info :

Pubmed ID

34521190

DOI: Digital Object Identifier

PMC8503986

Related Literature

Article Analysis
・Side Effects of alectinib
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.